# A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

> **NCT07633314** · PHASE2 · SUSPENDED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** TQC3927 inhalation aerosol
- **DRUG:** Glyceryl bromide/formoterol inhalation aerosol

## Key facts

- **NCT ID:** NCT07633314
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 90 (ESTIMATED)
- **Why stopped:** The sponsor has decided to suspend study progress. Further implementation of the study is pending notification.
- **Last updated:** 2026-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633314, "A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*